Immunoadsorption plasmapheresis for severe generalised myasthenia gravis

Area of Science:

• Neurology
• Immunology

Background:

• Myasthenia gravis (MG) is a rare autoimmune disorder affecting neuromuscular junctions, leading to muscle weakness.
• Severe generalized myasthenia gravis in childhood presents significant challenges in management and treatment.
• Current treatment options like plasma exchange carry risks such as viral infections and hypersensitivity reactions.

Observation:

• Two pediatric patients diagnosed with severe generalized myasthenia gravis were treated using immunoadsorption plasmapheresis.
• One patient was a 5-year-old girl, and the other was a 12-year-old girl.
• Treatment involved the removal of specific antibodies from the blood via immunoadsorption.

Findings:

• Both patients experienced dramatic improvements in bulbar symptoms and generalized muscle weakness.
• The treatment was well-tolerated, with no reported side effects in either patient.
• Immunoadsorption plasmapheresis demonstrated superior safety compared to conventional plasma exchange.

Implications:

• Immunoadsorption plasmapheresis is a highly effective and safe therapeutic option for pediatric severe generalized myasthenia gravis.
• This approach may offer a safer alternative to plasma exchange, reducing the risk of adverse events.
• Further research into immunoadsorption techniques could advance the treatment of autoimmune neuromuscular disorders in children.